Research progress of EGCG in the treatment of Alzheimer's disease

Changxing Liu,Lin Meng,Xiang Chang,Lili Yuan

DOI: https://doi.org/10.25236/ijfm.2022.040609

Abstract:: Alzheimer's disease (AD) is a degenerative disease of the nervous system. Mainly presenting with neuropsychiatric symptoms such as progressive memory impairment, cognitive dysfunction, personality changes, and language disorders [1] . Also known as senile dementia, it is the leading cause of dementia in the elderly [2] . Involved in 60-80% of all reports of dementia [3] . As the global population ages, AD prevalence and mortality rates increase. It seriously affects the quality of life of the elderly and brings a heavy economic burden and severe social problems. The tea polyphenol epigallocatechin gallate (EGCG) has preventive and therapeutic effects on Alzheimer's disease by inhibiting the amyloid formation and aggregation, antioxidant, anti-inflammatory, metal chelating, binding cholinesterase, thereby reducing the degradation of acetylcholine, and repairing mitochondrial dysfunction. This article reviews the research on the mechanism of EGCG action on Alzheimer's disease. necrosis and brain tissue damage have higher concentrations of Cu2 Zn2 +, and Fe3+ in the brain [50] , and EGCG has complexation for both Cu2 + and Fe3+ [51] The chelation of iron by EGCG interferes with iron-induced degradation and inactivation of iron regulatory protein (IRP1/2), leading to a decrease in amyloid precursor protein (APP) [52] It has been observed in electrochemistry and optics that EGCG inhibits the formation of Cu2+His complex by acting on Cu2+, thus reducing the formation of fiber [53] . EGCG also showed the ability to inhibit trivalent aluminum ion-induced Aβ42 fibrillation and significantly reduced Aβ42 toxicity by preventing further folding of Aβ42 monomers [54] . EGCG not only chelates free metal ions but also regulates the aggregation of Aβ after metal binding. In the effect of EGCG-bound metal ions on the structure of Aβ, it was found that the addition of EGCG to Cu 2+, Zn 2+ -bound Aβ generates free state Aβ aggregates, while structural Aβ aggregates are generated in metal-bound Aβ without the addition of EGCG [55] . These findings suggest that EGCG can compete with Aβ to bind metal ions, reduce APP production, prevent Aβ aggregation, and continue to inhibit Aβ aggregate binding after Aβ binding metal ions, thus preventing Aβ deposition and neurotoxicity.

Medicine